Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Caspaza S R O currently manages a focused patent portfolio within the Biotechnology & Pharmaceuticals technology area. The presence of 1 pending office action indicates a concentrated prosecution stage. This singular active matter suggests that the organization is maintaining a specific set of intellectual property assets rather than a broad filing strategy at this time.
The prosecution effort is characterized by centralization, as evidenced by the involvement of only 1 distinct examiner and 1 distinct art unit. Because there is 1 examiner for the 1 pending action, the entire active portfolio is subject to the scrutiny of a single individual. Such a structure limits the diversity of examiner perspectives but allows for a targeted response strategy within that specific administrative division.
RIGA, MICHAEL ANGELO serves as the busiest examiner for this portfolio, currently handling 1 busiest examiner pending office action. Because this examiner is responsible for the 1 pending action, the outcome of this matter is critical to the current success of the company's efforts in the Biotechnology & Pharmaceuticals sector. Practitioners should focus on the specific preferences of this individual examiner to optimize their prosecution results.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RIGA, MICHAEL ANGELO | 1 | 56.2% | +63.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18847461 | METHOD OF PREPARATION OF A BIOLOGICAL THERAPEUTIC PRODUCT BASED ON PERINATAL TISSUE, AND THE PRODUCT | RIGA, MICHAEL ANGELO | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18847461 | METHOD OF PREPARATION OF A BIOLOGICAL THERAPEUTIC PRODUCT BASED ON PERINATAL TISSUE, AND THE PRODUCT | RIGA, MICHAEL ANGELO | 1634 | §103 | Non-Final OA | — | Pending | Sep 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCaspaza S R O has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Michael Angelo Riga has the most, with 1 of Caspaza S R O's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
